Geron Corporation: Lackluster Share Price Performance Despite Reasonable Drug Launch

Geron Corporation (NASDAQ: GERN ) has been marketing Rytelo (imetelstat) for lower-risk myelodysplastic syndromes (LR-MDS) for a few quarters now, following US marketing approval in mid-2024. I rated GERN a hold in April 2024 as approval was somewhatScientist and trader of biotech stock. Focus on trading around events such as trial results and NDA/BLA approvals. Also covering companies in industries regulated by the FDA. Articles present my opinion on stocks, but don't constitute investment advice.Analyst’s ...